Invesco (IVZ)
NYSEFinancialsAsset ManagementSnapshot 2026-09-14
$31.51-2.39%
Close 2026-09-14 · 1-day change
NYSEFinancialsAsset ManagementSnapshot 2026-09-14
Research Workspace
Put IVZ beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Asset Management & Custody Banks is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — EPS growth to $2.03 in 2026: FY26 EPS guidance $0.71 vs $2.03 target.
View ThesisRevenue growth is accelerating — up about 12% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskInvesco's growth depends on delivering positive organic growth and strengthening its balance sheet. Revenue grew 20% year over year, and the last quarter beat expectations. It trades at 12.9× P/E versus a 15× peer median, indicating expectations look modest compared to our view. The primary risk is a potential guidance cut, with a 23% probability of missing outlook. Peer multiples imply a price about 21% above where it trades. This read is provisional.
Trailing returns as of 2026-09-14. IVZ is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering IVZ (as of Sep 2026).
Based on 3 Wall Street analysts offering 12-month price targets for IVZ in the last 4 months.
Continue this research
Compare IVZ with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| IVZ Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Asset Management & Custody Banks — fair value, gap to price, and forward P/E.
Compare the value case
Put IVZ next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Leadership change may impact regional growth strategies.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $31.51
The last 12 months of price, then the range of analyst 12-month targets from today’s $31.51.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Deliver positive organic growth
Resuming subscriptions may boost organic growth.
Threatens: Deliver positive organic growth
Fee cuts may hinder organic growth due to reduced revenue.
Threatens: Deliver positive organic growth
Fee reductions could lead to lower organic growth.
Advances: Deliver positive organic growth
Revamping platform supports positive organic growth objective.
Advances: Strengthen balance sheet and efficient capital deployment
Treasury buyback strengthens balance sheet and capital deployment.
Advances: Strengthen balance sheet and efficient capital deployment
New loans strengthen balance sheet and capital deployment strategy.
Advances: Deliver positive organic growth
Significant growth in loan originations supports organic growth objective.